艾复康胶囊对减轻热毒内蕴证HIV/AIDS患者HAART疗法毒副作用的临床观察  

Clinical observation on relieving adverse reaction from HAART in HIV/AIDS patients with the Redu Neiyun syndrome with the Aifukang capsule

作　　者：毛健[1] 王军文[2] 陈蕾[1] 欧松 

机构地区：[1]湖南中医药大学第二附属医院,湖南长沙410005 [2]湖南中医药大学,湖南长沙410208 [3]衡阳市第三人民医院,湖南衡阳421005

出　　处：《中医临床研究》2017年第24期70-72,共3页Clinical Journal Of Chinese Medicine

基　　金："十二五"国家科技重大专项艾滋病和病毒性肝炎等重大传染病防治(课题编号:2013ZX10005001)

摘　　要：目的:观察艾复康胶囊对于减轻热毒内蕴证型HIV/AIDS患者HAART疗法毒副作用的有效性及安全性,从而提高HAART疗法的依从性和成功率。方法:采用随机、双盲、安慰剂空白对照的临床试验方法,将50例初治HIV/AIDS患者,按1:1的比例分为治疗组和对照组。疗程24周,记录HAART疗法毒副作用发生情况,对治疗前后免疫指标、病毒载量进行数据分析。结果:(1)治疗组毒副发生比率及严重程度优于对照组;(2)免疫指标(CD4+T细胞计数):治疗组与对照组治疗后免疫指标均改善,但治疗组优于对照组(P<0.05);(3)病毒载量检测:治疗组与对照组治疗后病毒载量均下降(P>0.05),两组比较无统计学意义。结论:艾复康胶囊可减轻热毒内蕴证型艾滋病患者HAART疗法的不良反应及降低毒副作用的发生率,从而提高抗病毒治疗的依从性和成功率。Objective： To observe safety and the effect of the Aifukang capsule on adverse reaction from HAART in HIV/AIDS patients, in order to improve the compliance and success rate of HAART. Method： Randomized, double-blind, placebo-controlled clinical approach was applied in this study. 50 case of HIV/AIDS were randomly assigned to the treatment and placebo groups with 1： 1 ratio. The course of treatment lasted for 24 weeks. The occurrence of the adverse events was recorded and the data of viral load and immune indices（CD4 ＋ T cell） before and after the treatment were analyzed. Result： 1.The adverse reaction rate in the treatment group was better than the control group. Immune indices（CD4 ＋ T cell）： after the treatment, the immune index in the treatment group and the control group were both improved; and that in the treatment group was better（P〈0.05） 3. Viral load： after the treatment, the viral load in the treatment group and control group were decreased significantly（P 〉 0.05）. The comparison between the two groups showed no statistical significance. Conclusion： The Aifukang capsule could reduce the incidence of adverse reactions from HAART in HIV/AIDS patients, and improve the compliance and success rate of antiviral therapy.

关 键 词：艾复康胶囊 热毒内蕴证 HAART疗法 毒副作用 

分 类 号：R512.91[医药卫生—内科学]